Recent Updates
Recently added Catalysts
COCP Positive Sentiment Score: 75/100

Cocrystal Pharma to Participate in the H.C. Wainwright Global Investment Conference

Tuesday, September 5, 2023 1 min read
Key Takeaway: Cocrystal Pharma, a clinical-stage biopharmaceutical company, will participate in the H.C. Wainwright 25th Annual Global Investment Conference from September 11-13, 2023. The company's management will be available for one-on-one meetings with investors and industry professionals, providing opportunities for in-person and virtual interactions. A webcast of their presentation will be accessible starting September 11 at 7:00 a.m. Eastern time. Cocrystal focuses on developing antiviral therapeutics targeting viruses such as influenza, coronaviruses, and hepatitis C.

Market Sentiment Analysis

POSITIVE FACTORS

  • Cocrystal Pharma is actively participating in a significant investment conference.
  • The company is showcasing its commitment to developing novel antiviral therapeutics.
  • Management is engaging with institutional investors and industry professionals.

Full Press Release Details

BOTHELL, Wash., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”), a clinical-stage biopharmaceutical company dedicated to developing novel small molecule antiviral therapeutics, announces that management will participate in the H.C. Wainwright 25th Annual Global Investment Conference being held September 11-13, 2023. A webcast of the Cocrystal presentation will be available on the IR Calendar section of the Company’s website beginning Monday, September 11 at 7:00 a.m. Eastern time.
Management is available throughout the conference for in-person and virtual one-on-one meetings. Institutional investors and industry professionals can register to attend the conference virtually or in-person at the Lotte New York Palace Hotel.
About Cocrystal Pharma, Inc.
Cocrystal Pharma, Inc. is a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication process of influenza viruses, coronaviruses (including SARS-CoV-2 and noroviruses) and hepatitis C viruses. Cocrystal employs unique structure-based technologies and Nobel Prize-winning expertise to create first- and best-in-class antiviral drugs. For further information about Cocrystal, please visit www.cocrystalpharma.com.
LHA Investor Relations
Jabraham@jqapartners.com

Tags

Global Investment Conference
novel antiviral therapeutics

Frequently Asked Questions

What event will Cocrystal Pharma attend in September 2023?

Cocrystal Pharma will participate in the H.C. Wainwright 25th Annual Global Investment Conference.

When will the Cocrystal presentation be available online?

The Cocrystal presentation will be available on September 11 at 7:00 a.m. ET.

What type of therapeutics does Cocrystal Pharma develop?

Cocrystal develops novel antiviral therapeutics targeting influenza, coronaviruses, and hepatitis C.

How can investors meet with Cocrystal management during the conference?

Investors can schedule in-person or virtual one-on-one meetings throughout the conference.

Where can more information about Cocrystal be found?

More information about Cocrystal can be found on their website at www.cocrystalpharma.com.

Tags: COCP Viatris Investor Conferences Healthcare Cocrystal Pharma antiviral therapeutics investment conference H.C. Wainwright clinical-stage biotech
Last updated: Sep 5, 2023